Kessler Markus, Arai Amy C
Department of Pharmacology, Southern Illinois University School of Medicine, 801 N. Rutledge, PO Box 19629, Springfield, IL 62794-9629, USA.
Brain Res. 2006 Mar 3;1076(1):25-41. doi: 10.1016/j.brainres.2005.09.024. Epub 2005 Oct 26.
Compounds which modulate AMPA receptor function through allosteric mechanisms were examined for their effect on the binding of the agonist [3H]fluorowillardiine (FW). Benzamide-type positive modulators (ampakinestrade mark) under all experimental circumstances increased [3H]FW binding to native receptors in rat brain membranes. Benzothiadiazide drugs had more variable effects ranging from large reductions with cyclothiazide and JM-13 to increases produced by more recent compounds like PEPA, D1 and LY392098. These effects on binding were moderately influenced by the assay conditions, including temperature and the presence or absence of thiocyanate. Significant changes in agonist binding were also produced by other modulatory agents such as noncompetitive blockers (GYKI 53655, SYM 2206), polycationic compounds (spermine, Naspm, philanthotoxin) and polyanionic compounds (Evans Blue, suramin, PPNDS). EC50 values usually were similar to those from physiological studies, which validates using binding tests to assess drug potencies. Moreover, direction and magnitude of the binding change (Emax) provide information about which kinetic aspects are affected by a drug. For example, the magnitude of the binding increase produced by positive modulators was strongly correlated with their ability to slow response deactivation in excised patch recordings. Binding also provides a reliable method to examine whether interactions between agents are competitive. Thus, thiocyanate did not significantly influence the EC50 of cyclothiazide, suggesting distinct sites of action. Taken together, [3H]FW binding can yield important information about drug-receptor and drug-drug interactions for a wide range of modulatory agents. One potential limitation of [3H]FW is a large preference for subunits GluR1 and GluR2 (KD 4-10 nM) over GluR3 and GluR4 (160-600 nM) which implies that tests with brain membranes preferentially reveal drug effects produced at the former two subunits. Lastly, data are shown which highlight the importance of optimizing experimental conditions in filtration assays, for instance by always including thiocyanate in wash buffers.
研究了通过变构机制调节AMPA受体功能的化合物对激动剂[3H]氟维拉地辛(FW)结合的影响。在所有实验条件下,苯甲酰胺类正性调节剂(安帕金,商标名)均增加了[3H]FW与大鼠脑膜中天然受体的结合。苯并噻二嗪类药物的作用更具变异性,从环噻嗪和JM - 13导致的大幅降低到PEPA、D1和LY392098等较新化合物引起的增加。这些对结合的影响受到测定条件的适度影响,包括温度以及硫氰酸盐的存在与否。其他调节剂如非竞争性拮抗剂(GYKI 53655、SYM 2206)、聚阳离子化合物(精胺、Naspm、 philanthotoxin)和聚阴离子化合物(伊文思蓝、苏拉明、PPNDS)也会引起激动剂结合的显著变化。EC50值通常与生理学研究中的值相似,这验证了使用结合试验来评估药物效力的方法。此外,结合变化的方向和幅度(Emax)提供了有关药物影响哪些动力学方面的信息。例如,正性调节剂产生的结合增加幅度与其在膜片钳记录中减缓反应失活的能力密切相关。结合还提供了一种可靠的方法来检查药物之间的相互作用是否具有竞争性。因此,硫氰酸盐对环噻嗪的EC50没有显著影响,表明其作用位点不同。综上所述,[3H]FW结合可以为广泛的调节剂提供有关药物 - 受体和药物 - 药物相互作用的重要信息。[3H]FW的一个潜在局限性是它对亚基GluR1和GluR2(KD为4 - 10 nM)的偏好远高于GluR3和GluR4(160 - 600 nM),这意味着用脑膜进行的试验优先揭示在前两个亚基上产生的药物作用。最后,展示的数据突出了在过滤试验中优化实验条件的重要性,例如在洗涤缓冲液中始终加入硫氰酸盐。